EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
- PMID: 28397828
- PMCID: PMC5720366
- DOI: 10.1038/nrclinonc.2017.44
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
Abstract
The success of anticancer therapy is usually limited by the development of drug resistance. Such acquired resistance is driven, in part, by intratumoural heterogeneity - that is, the phenotypic diversity of cancer cells co-inhabiting a single tumour mass. The introduction of the cancer stem cell (CSC) concept, which posits the presence of minor subpopulations of CSCs that are uniquely capable of seeding new tumours, has provided a framework for understanding one dimension of intratumoural heterogeneity. This concept, taken together with the identification of the epithelial-to-mesenchymal transition (EMT) programme as a critical regulator of the CSC phenotype, offers an opportunity to investigate the nature of intratumoural heterogeneity and a possible mechanistic basis for anticancer drug resistance. In fact, accumulating evidence indicates that conventional therapies often fail to eradicate carcinoma cells that have entered the CSC state via activation of the EMT programme, thereby permitting CSC-mediated clinical relapse. In this Review, we summarize our current understanding of the link between the EMT programme and the CSC state, and also discuss how this knowledge can contribute to improvements in clinical practice.
Conflict of interest statement
The authors declare no competing interests.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5720366/bin/nihms922113f1.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5720366/bin/nihms922113f2.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5720366/bin/nihms922113f3.gif)
![Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5720366/bin/nihms922113f4.gif)
![Figure 5](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5720366/bin/nihms922113f5.gif)
Similar articles
-
Targeting microRNAs in epithelial-to-mesenchymal transition-induced cancer stem cells: therapeutic approaches in cancer.Expert Opin Ther Targets. 2015 Feb;19(2):285-97. doi: 10.1517/14728222.2014.975794. Epub 2015 Jan 7. Expert Opin Ther Targets. 2015. PMID: 25563894 Review.
-
Cancer stem cell (CSC) resistance drivers.Life Sci. 2019 Oct 1;234:116781. doi: 10.1016/j.lfs.2019.116781. Epub 2019 Aug 17. Life Sci. 2019. PMID: 31430455 Review.
-
Role of JAK/STAT3 Signaling in the Regulation of Metastasis, the Transition of Cancer Stem Cells, and Chemoresistance of Cancer by Epithelial-Mesenchymal Transition.Cells. 2020 Jan 15;9(1):217. doi: 10.3390/cells9010217. Cells. 2020. PMID: 31952344 Free PMC article. Review.
-
EMT, CTCs and CSCs in tumor relapse and drug-resistance.Oncotarget. 2015 May 10;6(13):10697-711. doi: 10.18632/oncotarget.4037. Oncotarget. 2015. PMID: 25986923 Free PMC article. Review.
-
Concise Review: Stem Cells and Epithelial-Mesenchymal Transition in Cancer: Biological Implications and Therapeutic Targets.Stem Cells. 2016 Aug;34(8):1997-2007. doi: 10.1002/stem.2406. Epub 2016 Jun 20. Stem Cells. 2016. PMID: 27251010 Review.
Cited by
-
Non-canonical mRNA translation initiation in cell stress and cancer.NAR Cancer. 2024 May 31;6(2):zcae026. doi: 10.1093/narcan/zcae026. eCollection 2024 Jun. NAR Cancer. 2024. PMID: 38828390 Free PMC article. Review.
-
Synergistic Immunoregulation: harnessing CircRNAs and PiRNAs to Amplify PD-1/PD-L1 Inhibition Therapy.Int J Nanomedicine. 2024 May 28;19:4803-4834. doi: 10.2147/IJN.S461289. eCollection 2024. Int J Nanomedicine. 2024. PMID: 38828205 Free PMC article. Review.
-
From immune equilibrium to tumor ecodynamics.Front Oncol. 2024 May 10;14:1335533. doi: 10.3389/fonc.2024.1335533. eCollection 2024. Front Oncol. 2024. PMID: 38807760 Free PMC article.
-
Extracellular vesicles in cancer cachexia: deciphering pathogenic roles and exploring therapeutic horizons.J Transl Med. 2024 May 27;22(1):506. doi: 10.1186/s12967-024-05266-9. J Transl Med. 2024. PMID: 38802952 Free PMC article. Review.
-
The intricate interplay between cancer stem cells and cell-of-origin of cancer: implications for therapeutic strategies.Front Oncol. 2024 May 10;14:1404628. doi: 10.3389/fonc.2024.1404628. eCollection 2024. Front Oncol. 2024. PMID: 38800385 Free PMC article. Review.
References
-
- Levan A, Hauschka TS. Endomitotic reduplication mechanisms in ascites tumors of the mouse. J Natl Cancer Inst. 1953;14:1–43. - PubMed
-
- Makino S. Further evidence favoring the concept of the stem cell in ascites tumors of rats. Ann NY Acad Sci. 1956;63:818–830. - PubMed
-
- Prehn RT. Analysis of antigenic heterogeneity within individual 3-methylcholanthrene-induced mouse sarcomas. J Natl Cancer Inst. 1970;45:1039–1045. - PubMed
-
- Mitelman F. The chromosomes of fifty primary Rous rat sarcomas. Hereditas. 1971;69:155–186. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources